Ferguson–Myrthil N – The efficacy of droxidopa in the management of symptomatic neurogenic hypotension was evaluated. It was highlighted in the accumulated evidence that as a treatment option for adult patients with symptomatic neurogenic orthostatic hypotension secondary to primary autonomic failure (Parkinson’s disease, multiple system atrophy, and pure autonomic failure), dopamine beta–hydroxylase deficiency, and nondiabetic autonomic neuropathy, droxidopa is safe and effective for treating orthostatic dizziness/lightheadedness, or the “feeling that you are about to black out”.